News

Additional small molecule compounds acting through the same target as LX9211 are also included in the exclusive arrangement.  LX9211 is currently completing IND-enabling studies, with Phase 1 clinical

Acromegaly is a rare endocrine disorder in which the body produces excessive growth hormone, leading to abnormal growth throughout the body over time.  The FDA's Orphan Drug Designation

Cherish, the study assessing Spinraza in later-onset SMA, found that children receiving the drug experienced a highly statistically-significant improvement in motor function compared to those who did not

The company will buy nearly seven million newly issued Aimmune’s common stock shares each priced at $19.20. Both Aimmune and Nestlé Health Science have also agreed to collaborate on

Livatag (doxorubicine Transdrug, a nanoparticle formulation of doxorubicin) is currently being evaluated clinically as a monotherapy in a Phase III ReLive trial for second-line advanced hepatocellular carcinoma (HCC). More

PARP is a naturally-occurring enzyme in the body that repairs damage to DNA in cells. While this repair is a useful process to maintain the integrity of healthy

NeoGAA is a second-generation enzyme replacement therapy being studied for the treatment of Pompe disease. Pompe disease is a progressive, debilitating and often fatal neuromuscular disease caused by

The approval of the company’s supplemental Biologics License Application makes it the first and only systemic therapy to treat pediatric patients aged 4 to 17 affected by the

In connection with the acquisition, EnBiotix has established EnBiotix. EnBiotix has also initiated a collaboration with Leipzig University and AMPT’s scientific co-founder, Professor Ralf Hoffmann, Ph.D. EnBiotix chairman